The Value of Surrogate Endpoints for Evaluation of Therapeutic Efficacy
- 1 July 1998
- journal article
- other
- Published by Springer Nature in Drug Information Journal
- Vol. 32 (3) , 737-743
- https://doi.org/10.1177/009286159803200313
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Newly licensed drugsBMJ, 1996
- Beware of Surrogate Outcome MeasuresInternational Journal of Technology Assessment in Health Care, 1996
- Use of composite endpoints in thrombolysis trials of acute myocardial infarctionThe American Journal of Cardiology, 1993
- Trends in Pharmaceutical DevelopmentDrug Information Journal, 1993
- Surrogate endpoints: A basis for a rational approachEuropean Journal of Clinical Pharmacology, 1992
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989
- Surrogate endpoints in clinical trials: Cardiovascular diseasesStatistics in Medicine, 1989
- Milrinone in congestive heart failure: Acute and chronic hemodynamic and clinical evaluationJournal of the American College of Cardiology, 1985